Omicron News and Research

RSS

How severe is Omicron compared to Delta?

Researchers assess the disease severity of hospitalized adult patients with COVID-19 through the use of three different health outcomes.

4 Jul 2022

SARS-CoV-2 infection of lung endothelial cells and pulmonary capillary microthrombosis

Researchers evaluated the presence of RNA of SARS-CoV-2 in lung tissue of deceased patients.

4 Jul 2022

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current uptick of cases in Germany.

1 Jul 2022

Scientists develop antibody test to keep track of immunity to SARS-CoV-2 variants

The experts agree - the pandemic is not over. Infections are ticking up again, fueled by the new variants our immune systems are ill prepared for.

1 Jul 2022

Remdesivir resistance in renal transplant patients with long COVID-19

A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.

1 Jul 2022

Somatic hypermutations found to enhance humoral immunity against SARS-CoV-2 variants

Researchers explored the molecular basis for increased immunity against heterologous SARS-CoV-2 strains after repeated antigen exposures.

1 Jul 2022

The antiviral effects of thiol drugs in COVID-19

A recent study investigated the effects of thiol drugs on SARS-CoV-2.

1 Jul 2022

The impact of pre-existing immunity on mRNA booster doses of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2

Researchers assessed the impact of pre-existing immunity on mRNA booster doses of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2.

1 Jul 2022

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.

30 Jun 2022

BNT162b2 vaccine induces moderate SARS-CoV-2 immunity in children 5 to 11

In a recent study published in the New England Journal of Medicine, researchers evaluated the effectiveness of the BNT162b2 vaccine against the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron in five to 11-year-old children.

30 Jun 2022

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

In a recent study published in The Lancet Infectious Diseases, researchers investigated the neutralization sensitivity of the emerging Omicron sub-variants, BA.2.12.1, BA.4, and BA.5.

30 Jun 2022

Rapid test can identify which variant has infected a COVID-19 patient in just a few hours

In just a few hours, UT Southwestern scientists can tell which variant has infected a COVID-19 patient – a critical task that can potentially influence treatment decisions but takes days or weeks at most medical centers.

30 Jun 2022

Age-specific susceptibility during the Omicron driven, Delta driven, and pre-Delta waves in South Korea

Researchers assessed the relative age-varying susceptibility to SARS-CoV-2 Omicron strain infections compared to the SARS-CoV-2 Delta strain and pre-Delta strains in South Korea.

30 Jun 2022

Effectiveness of Pfizer-BioNTech’s BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron variants among teens

Researchers evaluated Pfizer-BioNTech’s BNT162b2 vaccine effectiveness after two and three doses against SARS-CoV-2 variants of concern such as Delta and in Canadian adolescent community residents.

30 Jun 2022

The severity of Omicron BA.4/BA.5 lineages in the South Africa population

Researchers assessed the clinical severity of SARS-CoV-2 Omicron variants.

30 Jun 2022

South African study shows COVID severity of Omicron BA.1, BA.4, BA.5 all similar

A recent article posted to the medRxiv* preprint server analyzed the illness severity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/BA.5 and prior viral waves in the Western Cape, South Africa.

30 Jun 2022

Canada handled COVID well by most measures

In a recent study published in the Canadian Medical Association Journal, researchers assessed how Canada performed on all coronavirus disease 2019 (COVID-19)-related metrics compared to the group of 10 (G10) peer countries: France, Germany, Italy, Belgium, the Netherlands, Sweden, Switzerland, Japan, the United Kingdom, and the United States (US).

30 Jun 2022

How to develop an "all-variant" COVID vaccine

In a recent study published in Nature Immunology, researchers summarized their observations of humoral immune responses elicited in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infected people. Additionally, they discussed all the types of SARS-CoV-2 infection- and vaccine-induced neutralizing antibodies (nAbs).

30 Jun 2022

Researchers explore disease severity post-infection with SARS-CoV-2 Omicron in hematologic patients

A new study has studied the clinical outcome and spectrum in 61 patients infected with the SARS-CoV-2 Omicron variant.

29 Jun 2022

Study finds Omicron variant could break through vaccine protection more effectively than the Delta variant

Researchers assessed the efficacy of vaccinations against SARS-CoV-2 Delta and Omicron variants of concern.

29 Jun 2022

Omicron News and Research

How severe is Omicron compared to Delta?

SARS-CoV-2 infection of lung endothelial cells and pulmonary capillary microthrombosis

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

Scientists develop antibody test to keep track of immunity to SARS-CoV-2 variants

Remdesivir resistance in renal transplant patients with long COVID-19

Somatic hypermutations found to enhance humoral immunity against SARS-CoV-2 variants

The antiviral effects of thiol drugs in COVID-19

The impact of pre-existing immunity on mRNA booster doses of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

BNT162b2 vaccine induces moderate SARS-CoV-2 immunity in children 5 to 11

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Rapid test can identify which variant has infected a COVID-19 patient in just a few hours

Age-specific susceptibility during the Omicron driven, Delta driven, and pre-Delta waves in South Korea

Effectiveness of Pfizer-BioNTech’s BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron variants among teens

The severity of Omicron BA.4/BA.5 lineages in the South Africa population

South African study shows COVID severity of Omicron BA.1, BA.4, BA.5 all similar

Canada handled COVID well by most measures

How to develop an "all-variant" COVID vaccine

Researchers explore disease severity post-infection with SARS-CoV-2 Omicron in hematologic patients

Study finds Omicron variant could break through vaccine protection more effectively than the Delta variant

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News